Drug retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in Korean patients with seropositive rheumatoid arthritis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The aim of this study was to compare the short- and long-term retention rates of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) in Korean patients with seropositive rheumatoid arthritis. Methods: This study was conducted with 1,538 treatment courses of 1,063 patients, including adalimumab (n = 332), etanercept (n = 369), infliximab (n = 146), abatacept (n = 152), tocilizumab (n = 299), tofacitinib (n = 136), and baricitinib (n = 104), in patients with seropositive rheumatoid arthritis who started b/tsDMARD treatment between 2008 and 2020 at Seoul St. Mary’s Hospital. Discontinuation 1 and 3 years after the first prescription of each drug was investigated. Kaplan– Meier estimates of time to discontinuation were calculated to compare the difference in drug retention rate for each drug. Patient-level predictors of drug discontinuation were evaluated using a Cox proportional hazards model. Results: The overall 1-year drug retention rate was from 60.1% for adalimumab to 90.0% for tofacitinib in the b/tsDMARD-naïve group, and from 55.2% for infliximab to 84.8% for tofacitinib in the b/tsDMARD-experienced group. The 3-year drug retention rate was from 36.9% for infliximab to 86.5% for tofacitinib in the b/tsDMARD-naïve group, and from 31.0% for infliximab to 65.4% for tocilizumab in the b/tsDMARD-experienced group. Drug discontinuation appeared to be affected by specific types of b/tsDMARDs. Conclusions: Tocilizumab and tofacitinib are less commonly discontinued compared to tumor necrosis factor-α inhibitors at 1 and 3 years. Specifically, tofacitinib in the b/tsDMARD-naïve group and tocilizumab in the b/tsDMARD-experienced group showed the highest 3-year retention rates.
Abstract
Background/Aims: The aim of this study was to compare the short- and long-term retention rates of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) in Korean patients with seropositive rheumatoid arthritis. Methods: This study was conducted with 1,538 treatment courses of 1,063 patients, including adalimumab (n = 332), etanercept (n = 369), infliximab (n = 146), abatacept (n = 152), tocilizumab (n = 299), tofacitinib (n = 136), and baricitinib (n = 104), in patients with seropositive rheumatoid arthritis who started b/tsDMARD treatment between 2008 and 2020 at Seoul St. Mary’s Hospital. Discontinuation 1 and 3 years after the first prescription of each drug was investigated. Kaplan– Meier estimates of time to discontinuation were calculated to compare the difference in drug retention rate for each drug. Patient-level predictors of drug discontinuation were evaluated using a Cox proportional hazards model. Results: The overall 1-year drug retention rate was from 60.1% for adalimumab to 90.0% for tofacitinib in the b/tsDMARD-naïve group, and from 55.2% for infliximab to 84.8% for tofacitinib in the b/tsDMARD-experienced group. The 3-year drug retention rate was from 36.9% for infliximab to 86.5% for tofacitinib in the b/tsDMARD-naïve group, and from 31.0% for infliximab to 65.4% for tocilizumab in the b/tsDMARD-experienced group. Drug discontinuation appeared to be affected by specific types of b/tsDMARDs. Conclusions: Tocilizumab and tofacitinib are less commonly discontinued compared to tumor necrosis factor-α inhibitors at 1 and 3 years. Specifically, tofacitinib in the b/tsDMARD-naïve group and tocilizumab in the b/tsDMARD-experienced group showed the highest 3-year retention rates.
참고문헌 (27)
- Du Pan SM, "Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis", Arthritis Rheum, 61, pp.560~568 (2009)
- Favalli EG, "Twelve-year retention rate of first-line tumor necrosis factor inhibitors in rheumatoid arthritis : real-life data from a local registry", Arthritis Care Res(Hoboken), 68, pp.432~439 (2016)
- Singh JA, "2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis", Arthritis Rheumatol, 68, pp.1~26 (2016)
- Smolen JS, "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2019 update", Ann Rheum Dis, 79, pp.685~699 (2020)
- Choy EH, "Clinical significance of Janus Kinase inhibitor selectivity", Rheumatology(Oxford), 58, pp.953~962 (2019)
- O’Shea JJ, "JAKs and STATs in immunity, immunodeficiency, and cancer", N Engl J Med, 368, pp.161~170 (2013)
- Iwata S, "Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis", Expert Rev Clin Immunol, 12, pp.1047~1057 (2016)
- Marchesoni A, "TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice", Ann N Y Acad Sci, 1173, pp.837~846 (2009)
- Iannone F, "Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry : an appraisal of predictors", J Rheumatol, 39, pp.1179~1184 (2012)
- Du Pan SM, "Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients", Ann Rheum Dis, 71, pp.997~999 (2012)
- Jung JY, "Efficacy and drug retention of tofacitinib in rheumatoid arthritis : from the nationwide Korean College of Rheumatology Biologics registry", Clin Exp Rheumatol, 41, pp.1034~1041 (2023)
- Prior-Español A, "Clinical factors associated with discontinuation of ts", bDMARDs in rheumatic patients from the BIOBADASER III registry, 2021, pp.11, 11091~
- Mahlich J, "Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan", Patient Prefer Adherence, 10, pp.1509~1519 (2016)
- Ebina K, "Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis : the ANSWER cohort study", Arthritis Res Ther, 22, pp.142~ (2020)
- Choi S, "Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients : Cohort study in A real world setting", Semin Arthritis Rheum, 51, pp.685~691 (2021)
- Gabay C, "Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis : data from the Swiss Clinical Quality Management Registry", Rheumatology(Oxford), 54, pp.1664~1672 (2015)
- Moots RJ, "The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab : Results from a multinational, real-world clinical practice, non-interventional study", PLoS One, 12, pp.e0175207~ (2017)
- Vincent FB, "Antidrug antibodies(ADAb)to tumour necrosis factor(TNF)-specific neutralising agents in chronic inflammatory diseases : a real issue, a clinical perspective", Ann Rheum Dis, 72, pp.165~178 (2013)
- Strand V, "Immunogenicity of biologics in chronic inflammatory diseases : a systematic review", BioDrugs, 31, pp.299~316 (2017)
- Garcês S, "The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases : a systematic review of the literature with a meta-analysis", Ann Rheum Dis, 72, pp.1947~1955 (2013)
- Figueiredo IT, "Maintenance and tolerability of infliximab in a cohort of 152 patients with rheumatoid arthritis", Clin Exp Rheumatol, 26, pp.18~23 (2008)
- Ytterberg SR, "Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis", N Engl J Med, 386, pp.316~326 (2022)
- Bechman K, "A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis", Rheumatology(Oxford), 58, pp.1755~1766 (2019)
- Winthrop KL, "Herpes zoster and tofacitinib : clinical outcomes and the risk of concomitant therapy", Arthritis Rheumatol, 69, pp.1960~1968 (2017)
- Song YJ, "Risk factors for herpes zoster in Korean patients with rheumatoid arthritis treated with JAK inhibitor : a nested case-control study", RMD Open, 8, pp.e001892~ (2022)
- Smolen JS, "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2022 update", Ann Rheum Dis, 82, pp.3~18 (2023)
- Nagy G, "EULAR definition of difficult-to-treat rheumatoid arthritis", Ann Rheum Dis, 80, pp.31~35 (2021)